German HTA Assessment Knocks Back Gilenya In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
IQWiG’s failure to find any added benefit from Novartis’ oral MS drug Gilenya in two out of three of its target patient groups, on the grounds of insufficient evidence, puts pressure on the drug following a similarly negative recommendation by U.K. cost-watchdog NICE at the end of 2011.